Influence of brotizolam on the ventilatory and mouth-occlusion pressure response to hypercapnia in patients with chronic obstructive pulmonary disease.

Effect of 0.25 mg brotizolam on patients with chronic obstructive lung disease of moderate to severe degree was studied. There was no difference between the slopes of ventilation vs alveolar CO2 for brotizolam and placebo as compared with base line values. Mouth-occlusion pressures did not change under the influence of drug or placebo. Brotizolam (0.25 mg) is without adverse side-effects on respiratory centre output or on mechanics of ventilation.

RCT Entities:   Population Interventions Outcomes